BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22297111)

  • 41. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
    Leurs R; Bakker RA; Timmerman H; de Esch IJ
    Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
    Ghorai P; Kraus A; Keller M; Götte C; Igel P; Schneider E; Schnell D; Bernhardt G; Dove S; Zabel M; Elz S; Seifert R; Buschauer A
    J Med Chem; 2008 Nov; 51(22):7193-204. PubMed ID: 18950149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
    McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
    J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
    J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
    Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histamine H3 receptor as a drug discovery target.
    Berlin M; Boyce CW; Ruiz Mde L
    J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
    [No Abstract]   [Full Text] [Related]  

  • 48. The evolution of histamine H₃ antagonists/inverse agonists.
    Lebois EP; Jones CK; Lindsley CW
    Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New high affinity H3 receptor agonists without a basic side chain.
    Kitbunnadaj R; Hoffmann M; Fratantoni SA; Bongers G; Bakker RA; Wieland K; el Jilali A; De Esch IJ; Menge WM; Timmerman H; Leurs R
    Bioorg Med Chem; 2005 Dec; 13(23):6309-23. PubMed ID: 16213736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.
    Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5384-8. PubMed ID: 21783360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B; Elz S; Pertz HH; Stark H; Schunack W
    Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
    Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
    J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
    Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
    Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice.
    Huang ZL; Mochizuki T; Qu WM; Hong ZY; Watanabe T; Urade Y; Hayaishi O
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4687-92. PubMed ID: 16537376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
    Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
    Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach.
    Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R
    Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.